{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:55:07Z","timestamp":1775710507797,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> This study aims to investigate the clinical efficacy of Ganshuang granules combined with tenofovir, an antiviral drug, in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A total of 92 patients with chronic hepatitis B combined with non-alcoholic fatty liver who were treated in our Hospital from January 2020 to December 2021 were included as the research objects. According to the method of random number table, the patients were divided into the control group (<jats:italic>n<\/jats:italic> = 42) and the treatment group (<jats:italic>n<\/jats:italic> = 50). The control group was treated with silibinin meglumine tablets and tenofovir, while the treatment group was treated with Ganshuang granules combined with silybin meglumine tablets and tenofovir. Before and after treatment, liver function index, liver hardness measurement (LSM), controlled attenuation parameter (CAP), HBV-DNA serum load and body mass index (BMI) were observed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Compared with the baseline, ALT, AST and GGT were significantly improved in both groups after treatment (<jats:italic>p<\/jats:italic> &amp;lt; 0.05), while TBIL indexes were not significantly different before and after treatment (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). Patients in the treatment group had significantly lower ALT and AST index values than the control group at 12 and 24\u00a0weeks of treatment (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). At 12 and 24\u00a0weeks of treatment, the fat attenuation parameters of the two groups were significantly decreased compared with those before treatment, and the difference was statistically significant (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). The fat attenuation parameters in the treatment group were significantly lower than those in the control group at 12 and 24\u00a0weeks after treatment (<jats:italic>p<\/jats:italic> &amp;lt; 0.05).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The effect of Ganshuang granule combined with antiviral drugs in the treatment of chronic hepatitis B complicated with non-alcoholic fatty liver is significantly better than that of antiviral drugs alone, which is worthy of clinical recommendation.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>https:\/\/register.clinicaltrials.gov<\/jats:ext-link>, identifier NCT05523648.<\/jats:p>","DOI":"10.3389\/fphar.2022.1032789","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T05:21:12Z","timestamp":1670995272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Changtian","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1177\/2050640617751252","article-title":"Risk factors associated with liver steatosis and fibrosis in chronic Hepatitis B patient with component of metabolic syndrome","volume":"6","author":"Cai","year":"2018","journal-title":"United Eur. Gastroenterol. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/jgh.13536","article-title":"Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic Hepatitis B","volume":"32","author":"Chan","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"11383","DOI":"10.3390\/ijms222111383","article-title":"The ameliorative effects of saikosaponin in thioacetamide-induced liver injury and non-alcoholic fatty liver disease in mice","volume":"22","author":"Chang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum Hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e72049","DOI":"10.1371\/journal.pone.0072049","article-title":"Inverse association between Hepatitis B virus infection and fatty liver disease: A large-scale study in populations seeking for check-up","volume":"8","author":"Cheng","year":"2013","journal-title":"PloS one"},{"key":"B6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/hep.30857","article-title":"Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B","volume":"71","author":"Choi","year":"2020","journal-title":"Hepatol. Baltim. Md.)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: A Korean nationwide cohort study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"28734","DOI":"10.1038\/srep28734","article-title":"New insights into salvianolic acid A action: Regulation of the TXNIP\/NLRP3 and TXNIP\/ChREBP pathways ameliorates HFD-induced NAFLD in rats","volume":"6","author":"Ding","year":"2016","journal-title":"Sci. Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3969\/j.issn.1001-5256.2018.10.010","article-title":"Consensus on diagnosis and treatment of nonalcoholic fatty liver disease and related metabolic disorders (2nd edition)","volume":"34","year":"2018","journal-title":"J. Clin. Hepatobiliary Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/978-3-319-48382-5_19","article-title":"Non-alcoholic fatty liver disease","volume":"960","author":"Engin","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: From obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol. Metab. Syndr."},{"key":"B12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.intimp.2016.11.022","article-title":"The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic Hepatitis B and HBV related cirrhosis: A systematic review and meta-analysis","volume":"42","author":"Han","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/oby.21333","article-title":"Relationship between chronic Hepatitis B and metabolic syndrome: A structural equation modeling approach","volume":"24","author":"Huang","year":"2016","journal-title":"Obes. (Silver Spring, Md.)"},{"key":"B14","first-page":"26","article-title":"Guidelines for prevention and treatment of chronic hepatitis B (2019 edition)","volume":"10","year":"2020","journal-title":"China J. Viral Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.3390\/cancers13102301","article-title":"The FIB-4 index is a useful predictor for the development of hepatocellular carcinoma in patients with coexisting nonalcoholic fatty liver disease and chronic hepatitis B","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3350\/cmh.2018.0040","article-title":"Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic Hepatitis B","volume":"25","author":"Lee","year":"2019","journal-title":"Clin. Mol. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12951-018-0391-9","article-title":"Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD","volume":"16","author":"Liang","year":"2018","journal-title":"J. Nanobiotechnology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/j.gastro.2014.02.033","article-title":"Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic Hepatitis B treated with entecavir vs lamivudine","volume":"147","author":"Lim","year":"2014","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.metabol.2012.07.022","article-title":"Combined effects of Hepatitis B virus infection and elevated alanine aminotransferase levels on dyslipidemia","volume":"62","author":"Liu","year":"2013","journal-title":"Metabolism."},{"key":"B20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12876-019-0966-4","article-title":"Serum HBV RNA quantification: Useful for monitoring natural history of chronic Hepatitis B infection","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Gastroenterol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11655-015-2430-9","article-title":"Protective effect of Ganshuang granules on liver cirrhosis by suppressing regulatory T cells in mouse model","volume":"25","author":"Liu","year":"2019","journal-title":"Chin. J. Integr. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3748\/wjg.v17.i18.2288","article-title":"Silybin and the liver: From basic research to clinical practice","volume":"17","author":"Loguercio","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/s0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet (London, Engl."},{"key":"B24","doi-asserted-by":"publisher","first-page":"624","DOI":"10.19852\/j.cnki.jtcm.2021.03.015","article-title":"Effect of entecavir plus Ganshuang granule on fibrosis and cirrhosis in patients with chronic Hepatitis B","volume":"41","author":"Lu","year":"2021","journal-title":"J. traditional Chin. Med. = Chung i tsa chih ying wen pan"},{"key":"B25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41598-020-80709-z","article-title":"Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic Hepatitis B","volume":"11","author":"Lv","year":"2021","journal-title":"Sci. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"660179","DOI":"10.3389\/fimmu.2021.660179","article-title":"The role of the gut-liver Axis in metabolic dysfunction-associated fatty liver disease","volume":"12","author":"Mart\u00edn-Mateos","year":"2021","journal-title":"Front. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"6613827","DOI":"10.1155\/2021\/6613827","article-title":"NAFLD, insulin resistance, and diabetes mellitus type 2","volume":"2021","author":"Maru\u0161i\u0107","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12875-020-01306-7","article-title":"Non-alcoholic fatty liver disease (NAFLD) and the cardiovascular disease (CVD) risk categories in primary care: Is there an association?","volume":"21","author":"Miptah","year":"2020","journal-title":"BMC Fam. Pract."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/j.1440-1746.2008.05478.x","article-title":"Hepatic steatosis in chronic Hepatitis B patients is associated with metabolic factors more than viral factors","volume":"23","author":"Peng","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1478-3231.2011.02453.x","article-title":"Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection","volume":"31","author":"Petta","year":"2011","journal-title":"Liver Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/s0140-6736(15)61412-x","article-title":"Estimations of worldwide prevalence of chronic Hepatitis B virus infection: A systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet (London, Engl."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e5995","DOI":"10.7759\/cureus.5995","article-title":"Effect of non-alcoholic fatty liver disease on transaminase levels and transient Elastography in patients with chronic hepatitis B","volume":"11","author":"Sharif","year":"2019","journal-title":"Cureus"},{"key":"B33","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/jcmm.12994","article-title":"Naringin in Ganshuang Granule suppresses activation of hepatic stellate cells for anti-fibrosis effect by inhibition of mammalian target of rapamycin","volume":"21","author":"Shi","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e15732","DOI":"10.1097\/md.0000000000015732","article-title":"The efficacy of Chinese patent medicine combined with entecavir for the treatment of chronic HBV-related liver fibrosis or cirrhosis: Protocol for a systematic review and meta-analysis of randomized controlled trials or prospective cohort studies","volume":"98","author":"Song","year":"2019","journal-title":"Medicine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1590\/1414-431x20122551","article-title":"Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver","volume":"46","author":"Yao","year":"2013","journal-title":"Braz. J. Med. Biol. Res. = Revista brasileira de pesquisas medicas e Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12876-018-0773-3","article-title":"Case report: Lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic Hepatitis B","volume":"18","author":"Ying","year":"2018","journal-title":"BMC Gastroenterol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatol. Baltim. Md.)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e22692","DOI":"10.1097\/md.0000000000022692","article-title":"Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic Hepatitis B liver fibrosis: A protocol for systematic review and meta analysis","volume":"99","author":"Zeng","year":"2020","journal-title":"Medicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3951574","DOI":"10.1155\/2019\/3951574","article-title":"Transient Elastography and ultrasonography: Optimal evaluation of liver fibrosis and cirrhosis in patients with chronic hepatitis B concurrent with nonalcoholic fatty liver disease","volume":"2019","author":"Zhang","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e2100520","DOI":"10.1002\/cbdv.202100520","article-title":"Traditional Chinese medicine Ganshuang granules attenuate CCl(4) -induced hepatic fibrosis by modulating gut microbiota","volume":"18","author":"Zhao","year":"2021","journal-title":"Chem. Biodivers."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1032789\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T05:21:17Z","timestamp":1670995277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1032789\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":40,"alternative-id":["10.3389\/fphar.2022.1032789"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1032789","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"article-number":"1032789"}}